Monomethyl auristatin E, a potent cytotoxic payload for development of antibody-drug conjugates against breast cancer
Novelty in Biomedicine. 2017; 5 (3): 98-103
em Inglês
| IMEMR
| ID: emr-188711
ABSTRACT
Background:
Breast cancer is a heterogeneous disease characterized by differential responses to targeted and chemotherapeutic agents. Antibody-drug conjugates are one of the promising strategies for the treatment of breast cancer. Monomethyl auristatin E [MMAE] is a highly potent microtubule inhibitor and a common payload used for development of antibody-drug conjugates. The purpose of this study was to investigate the cytotoxic effects of MMAE on breast cancer cell lines
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Idioma:
Inglês
Revista:
Novelty Biomed.
Ano de publicação:
2017
Similares
MEDLINE
...
LILACS
LIS